2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK
  3. EGFR
  4. Petosemtamab

Petosemtamab  (Synonyms: MCLA 158)

Cat. No.: HY-P99406 Pureza: 99.94%
COA
SDS
Technical Support

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC).

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 2213450-26-9

Tamaño Precio Stock Cantidad
Muestra gratis (100 μg)   Solicite ahora  
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Petosemtamab Related Antibodies

Top Publications Citing Use of Products

Ver todos los productos específicos de isoformas EGFR:

Ver todas las isoformas
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC)[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[2]

EGFR

0.22 nM (Kd)

LGR5

0.85 nM (Kd)

In Vitro

Petosemtamab (MCLA 158) (1 µg/mL, 24 or 72 h) leads to EGFR degradation in EGFR+/LGR5+ colorectal cancer organoids[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Petosemtamab Related Antibodies

Western Blot Analysis[2]

Cell Line: P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids
Concentration: 1 µg/mL
Incubation Time: 1, 6, 24, 72 h
Result: Time-dependently degraded EGFR.
In Vivo

Petosemtamab (MCLA 158) (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Esophageal squamous, gastric adenocarcinoma and head & neck PDX models[2]
Dosage: 25 mg/kg/week
Administration: Intravenous injection (i.v.) for 6 weeks.
Result: Inhibited tumor growth.
Ensayo clínico
Gene ID

8549  [NCBI] & 8549  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Peso molecular

145.5 kDa

No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Petosemtamab]
Envío

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized EGFR Protein, Human (621a.a, CHO, His, HY-P7340) can bind Petosemtamab. The EC50 for this effect is 4.45 ng/mL.
  • Immobilized HY-P79308 Lgr5/GPR49 Protein, Human (CHO, hFc) can bind Petosemtamab. The EC50 for this effect is 85 ng/mL.
Pureza y Documentación

Purity: 99.94%

SDS (251 KB)

COA (232 KB) SDS-PAGE (453 KB) SEC-HPLC (399 KB)

Inhibitory Antibodies User Guide (603 KB)
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Petosemtamab Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Petosemtamab2213450-26-9MCLA 158MCLA158MCLA-158EGFREpidermal growth factor receptorErbB-1HER1CRCcolorectal cancerHNSCChead and neck squamous cell carcinomaEGFR degradationInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Petosemtamab
Cat. No.:
HY-P99406
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.